GLENMARK2,403.10

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹67,815 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
GLENMARK
FY26
DRREDDY
FY26
LUPIN
FY26
ALKEM
FY26
Peer
Median
Valuation — at last close
P/E49.79×22.63×17.76×26.55×22.63× +120%
P/B6.45×2.49×4.21×4.26×4.21× +53%
EV/EBITDA14.57×14.91×10.55×20.54×14.91× -2%
Market Cap₹67,815 Cr₹95,274 Cr₹94,823 Cr₹61,102 Cr₹94,823 Cr -28%
Growth
Revenue CAGR 3Y9.34%10.96%18.88%8.25%10.96% -15%
Revenue CAGR 5Y9.19%12.09%13.02%10.09%12.09% -24%
Net Income CAGR 3Y53.39%-2.66%128.70%32.67%32.67% +63%
Revenue YoY (latest Q)23.10%-5.51%32.04%10.95%10.95% +111%
Net Income YoY (latest Q)927.88%-69.10%16.01%-22.00%-22.00% +4318%
Profitability
EBITDA Margin26.92%19.15%31.53%20.43%20.43% +32%
Net Income Margin8.02%12.34%19.16%15.98%15.98% -50%
Return on Common Equity0.00%10.98%23.69%16.04%16.04% -100%
Return on Capital Employed29.55%10.62%28.94%16.30%16.30% +81%
Return on Assets6.84%7.15%13.96%11.26%11.26% -39%
Credit & Quality
Total Debt/Equity0.00×0.16×0.26×0.11×0.16× -100%
Interest Coverage19.16×11.76×17.12×16.32×16.32× +17%
Scale — latest FY
Revenue / Total Income₹16,983 Cr₹33,700 Cr₹27,958 Cr₹14,712 Cr₹27,958 Cr -39%
Net Income₹1,362 Cr₹4,158 Cr₹5,355 Cr₹2,351 Cr₹4,158 Cr -67%
Total Assets₹19,908 Cr₹58,123 Cr₹38,365 Cr₹20,873 Cr₹38,365 Cr -48%
EPS₹48.26₹50.41₹116.75₹192.51₹116.75 -59%
Book Value per Share₹372.49₹457.86₹492.42₹1,200.25₹492.42 -24%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.